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OBJECTIVES This study was designed to evaluate the effect of periprocedural myocardial infarction (MI) on
mortality according to success of the stent procedure.
BACKGROUND The mortality effect of periprocedural MI relative to successful versus unsuccessful procedures
has not been examined.
METHODS All-cause mortality during the first year was evaluated prospectively among 5,850 patients
from coronary stent clinical trials. Myocardial infarction was classified according to creatine
kinase-MB level as type 1 (1 but 3 times normal), type 2 (3 but 8 times normal), or
type 3 (8 times normal or Q-wave MI). Procedures were classified as successful unless there
was a final diameter stenosis 50%; final Thrombolysis In Myocardial Infarction flow grade
3; final National Heart, Lung, and Blood Institute dissection grade D; repeat revascu-
larization within 24 h; or stent thrombosis within 24 h.
RESULTS Myocardial infarction was more frequent after unsuccessful procedures (69.6% vs. 20.4%, p
0.001). Mortality during the first year was higher in patients with MI (2.8% vs. 1.7%, p 
0.01), but the effect was significant only for type 3 MI (4.7% vs. 1.7%, p 0.008). Moreover,
the mortality difference for any MI was confined to patients with unsuccessful procedures
(13.1% vs. 0%, p  0.03), with no significant effect among patients with otherwise successful
procedures (2.1% vs. 1.7%, p  0.20). The independent predictors of mortality were
unsuccessful procedure (p  0.001), diabetes mellitus (p  0.001), history of prior MI (p 
0.003), multivessel disease (p  0.006), and advancing age (p  0.001), but not periproce-
dural MI.
CONCLUSIONS The association of periprocedural MI with increased mortality during the first year following
stent placement was confined to patients with unsuccessful procedures. (J Am Coll Cardiol
2004;44:1210–4) © 2004 by the American College of Cardiology Foundationf
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the incidence of creatine kinase-MB (CK-MB) isoenzyme
levation after percutaneous coronary intervention (PCI)
anges from 11% to 35% (1,2), including low-level eleva-
ions (3 times normal) with no associated signs or symp-
oms as well as large non–Q-wave (CK-MB 8 times
ormal) and Q-wave myocardial infarction (MI). Whereas
he deleterious effect on survival of large periprocedural MIs
as been well documented (3), the clinical impact of isolated
K-MB elevation following otherwise successful proce-
ures remains controversial. Some studies have reported
hat mild to moderate CK-MB elevation after interven-
ional procedures has no adverse clinical consequences
1–3), whereas others have found that even minimal eleva-
ions are associated with increased mortality (4–6). Many of
hese studies, however, had methodologic limitations, in-
luding retrospective analysis, incomplete ascertainment of
K-MB data, or failure to control for potentially confound-
ng covariates. One potential confounder is the success of
he procedure itself, and the fundamental question remains
hether isolated enzyme elevation after “otherwise success-
From the *Harvard Clinical Research Institute, †Division of Cardiology, Beth
srael Deaconess Medical Center, and the ‡Division of Cardiology, Brigham and
omen’s Hospital, Boston, Massachusetts.
Manuscript received March 17, 2004; revised manuscript received May 5, 2004,cccepted June 7, 2004.ul” procedures has an independent impact on subsequent
urvival (7).
Unsuccessful procedures may result from angiographic
omplications occurring during the procedure, such as
evere dissections associated with impaired flow and/or
cute vessel closure, or from early clinical events such as
tent thrombosis. Any of these failure modes may be
ssociated with periprocedural MI and thus severely con-
ound analyses of effect on subsequent mortality.
We hypothesized that periprocedural MI would have
ignificantly different effects on early survival after coronary
tenting, depending on success of the index procedure.
ETHODS
atient population. Patients enrolled in six major clinical
rials of native coronary artery stenting with relatively
omogenous inclusion criteria and study protocols were
ligible. The details of the study protocols and justification
or pooling have been previously reported (8). Briefly, the
opulation included 6,186 patients who underwent stenting
f 6,219 native target vessels. All of the studies utilized the
ame angiographic core laboratory, and all CK-MB eleva-
ions were reviewed by an independent clinical events
ommittee, classifying MIs according to a previously re-
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September 15, 2004:1210–4 CK-MB Elevation, Procedural Success, and Mortalityorted MI classification scheme (9). Patients with baseline
K or CK-MB elevation or with clinical evidence of acute
I (n  117) were classified as having a preprocedure MI
nd were excluded from this analysis. Patients in whom CK
ata were incomplete (missing CK and/or CK-MB before
CI, after PCI, or both; n  219 [3.6%]) were also
xcluded, leaving 5,850 patients (5,880 treated lesions) for
nalysis.
ardiac enzyme determination and myocardial infarction
lassification. Creatine kinase and CK-MB measurements
ere made preprocedure, 6 to 12 h postprocedure, and at
he earlier of 24 h postprocedure or hospital discharge. The
-wave MI was defined as the development of new patho-
ogic Q waves (at least one mV in depth and 40 ms in
uration) in two or more contiguous leads. Myocardial
nfarction was then classified as follows:
ype 1: CK-MB 1 and 3 times normal (total CK 1
and 2 times normal if CK-MB data missing) in the
absence of new Q waves.
ype 2: CK-MB 3 and 8 times normal (total CK 2
and 3 times normal if CK-MB data missing) in the
absence of new Q waves.
ype 3: New Q-wave MI assessed with CK-MB 1 times
normal or CK-MB 8 times normal (total CK 3
times normal if CK-MB not available).
tudy definitions. The primary outcome was cumulative
ll-cause mortality. Procedures were considered unsuccess-
ul if final diameter stenosis was 50%; final Thrombolysis
n Myocardial Infarction flow grade was 3; final National
eart, Lung, and Blood Institute dissection was grade D;
r if the patient developed stent thrombosis or required
rgent repeat revascularization within 24 h.
Abbreviations and Acronyms
CK-MB  creatine kinase-MB
MI  myocardial infarction
PCI  percutaneous coronary intervention
able 1. Baseline Patient Characteristics
No MI
(n  4,602)
n (%)
ge, yrs (mean  SD) 62  11
emale 1,394 (30.3)
revious MI 1,494 (33.1)
urrent smoking 1,001 (21.8)
yslipidemia* 1,936 (42.8)
iabetes mellitus 988 (21.5)
ypertension 2,614 (57.2)
revious CABG 394 (8.6)
estenosis 555 (12.1)
ultivessel disease 1,496 (32.5)
nstable angina 1,943 (42.2)
jection fraction, % (mean  SD) 56  11
Defined as total cholesterol 200 mg/dl or on lipid-lowering therapy. The p value
CABG  coronary artery bypass grafting; MI  myocardial infarction.tatistical methods. Analyses were performed using SAS
or Windows version 6.12 (SAS Institute, Cary, North
arolina). Continuous variables were expressed as mean 
D and were compared using analysis of variance. Discrete
ariables were expressed as proportions and were compared
sing chi-square statistics. The effects of baseline clinical
nd angiographic variables as well as of procedural MI and
rocedural success on mortality were assessed using Cox
roportional hazards regression. One-year mortality was
valuated using Kaplan-Meier survival analysis and com-
ared using the log-rank statistic. Results were considered
tatistically significant at p  0.05.
ESULTS
aseline patient and lesion characteristics. Tables 1 and
show baseline patient and lesion characteristics. Patients
ho sustained a periprocedural MI were slightly older and
ere more likely to have had a prior MI, unstable angina
resentation, multivessel disease, and de novo lesions
reated. Pretreatment lesion length was also significantly
onger for MI patients and was progressively longer for each
igher MI classification.
ncidence of myocardial infarction and relationship to
rocedure success. Of the 5,850 patients, 1,248 (21.3%)
ustained a periprocedural MI, including 738 (12.6%) type
, 356 (6.1%) type 2, and 154 (2.6%) type 3 MI. Using the
tudy definition, the procedure was unsuccessful in 115
2.0%) patients. Figure 1 demonstrates the significant dif-
erence in MI frequency according to procedure success. Of
ote, although the MI rate was 20.4% after successful
rocedures, it was significantly higher after unsuccessful
rocedures (69.6%, p  0.0001), with a greater difference
or the larger type 3 MIs (32.2% vs. 2.0%, p  0.0001).
ype 3 MIs thus accounted for only 10% of all MIs after a
uccessful procedure, compared with 46% of the MIs seen
fter an unsuccessful procedure.
ortality. The follow-up duration was 300  90 days.
verall unadjusted mortality was 1.9% and was significantly
e 1
738)
%)
Type 2
(n  356)
n (%)
Type 3
(n  154)
n (%) p Value
11 64  11 63  12 0.001
31.6) 119 (33.4) 51 (33.1) 0.20
36.8) 122 (34.7) 66 (43.1) 0.02
22.0) 62 (17.4) 32 (20.8) 0.20
40.2) 133 (37.6) 60 (39.7) 0.15
18.3) 75 (21.1) 28 (18.2) 0.19
59.6) 227 (63.8) 90 (58.4) 0.08
9.5) 30 (8.4) 16 (10.4) 0.20
8.3) 29 (8.2) 15 (9.7) 0.004
36.2) 139 (39.0) 66 (42.9) 0.002
40.0) 167 (46.9) 77 (50.0) 0.04
11 56  12 57  11 0.20
t a comparison across the four groups of no MI and the three MI classes.Typ
(n 
n (
64 
233 (
268 (
162 (
293 (
135 (
436 (
70 (
61 (
267 (
295 (
55 
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CK-MB Elevation, Procedural Success, and Mortality September 15, 2004:1210–4igher among patients with periprocedural MI compared
ith those without (Fig. 2). There was a suggestion of
igher mortality with increasing MI type, but only type 3
I demonstrated significantly higher mortality compared
ith patients with no MI (4.7% vs. 1.7%, p  0.008).
oreover, the adverse effect of any MI on mortality was
onfined to patients who had unsuccessful procedures.
hen analysis was restricted to patients with successful
rocedures, mortality was similar for those with or without
I (2.1% vs. 1.7%, p  0.20) and by MI type. Survival
urves for MI types and those with no MI over the first year
re shown in Figure 3A for the overall group and in Figure
B for patients with otherwise successful procedures.
The independent predictors of mortality are shown in
able 3. Neither MI versus no MI or any MI type was
ignificantly associated with mortality after adjustment for
n unsuccessful procedure or in an analysis restricted to
uccessful patients.
igure 1. Incidence of periprocedural myocardial infarction by type (type
 creatine kinase-MB [CK-MB] isoenzyme 1 but 3 times normal;
ype 2  CK-MB elevation 3 but 8 times normal; type 3  8 times
ormal or Q-wave myocardial infarction) after coronary intervention in
able 2. Baseline Angiographic and Procedural Characteristics
No MI
(n  4,621)
arget vessel
Left main, n (%) 17 (0.4)
LAD, n (%) 1,912 (41.4)
LCX, n (%) 919 (19.9)
RCA, n (%) 1,773 (38.4)
essel diameter, mm, mean  SD 2.98  0.51
reprocedure MLD, mm, mean  SD 1.04  0.44
ostprocedure MLD, mm, mean  SD 2.82  0.43
esion length, mm, mean  SD 12.6  6.8
mplanted stent length, mm, mean  SD 20.9  10.8
lycoprotein IIb/IIIa inhibitor, n (%) 355 (7.7)
value reflects a chi-square statistic comparing no MI and the three MI classes. Th
LAD  left anterior descending coronary artery; LCX  left circumflex coronar
oronary artery.atients with successful and unsuccessful procedures.ISCUSSION
his prospective study of 5,850 patients undergoing bare
etal coronary stenting is the first analysis of the differential
mpact of periprocedural MI on mortality during the first
ear relative to procedure success. The results demonstrate
hat the association of MI with mortality during this interval
s limited to those patients with clearly defined and evident
nsuccessful procedures. Indeed, the association of an un-
uccessful procedure with MI carries an ominous prognosis.
n contrast, successful procedures with or without proce-
ural MI and unsuccessful procedures without associated
K-MB elevation have excellent early survival.
omparison with other studies. Previous studies on the
linical significance of elevated cardiac markers after PCI
ave produced a spectrum of results (2,3,6,9). Few question
he importance of large periprocedural MI, but the incon-
istency of data for an association of mortality with lower
evel CK-MB elevation has nurtured an ongoing debate
hether enzyme elevation after otherwise successful PCI
ctually affects survival.
At least part of the confusion arises from inadequate
igure 2. Mortality among patients with and without periprocedural
yocardial infarction (MI) by type (definitions as in Figure 1) and for
uccessful and unsuccessful procedures.
ype 1
 744)
Type 2
(n  359)
Type 3
(n  156) p Value
(0.3) 0 0 0.001
(41.0) 151 (42.1) 59 (37.8)
(25.8) 102 (28.4) 43 (27.6)
(32.9) 106 (29.5) 54 (34.6)
5  0.51 2.98  0.53 2.99  0.54 0.20
3  0.38 1.01  0.43 0.96  0.41 0.20
8  0.44 2.80  0.46 2.70  0.55 0.004
4  7.3 14.5  8.0 15.0  8.5 0.001
8  13.4 25.6  15.8 31.9  24.6 0.001
(7.3%) 35 (9.8%) 22 (14.3) 0.01
lues reflect a comparison across the four groups of no MI and 3 MI classes.
y; MI  myocardial infarction; MLD  minimum lumen diameter; RCA  rightT
(n
2
305
192
245
2.9
1.0
2.7
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September 15, 2004:1210–4 CK-MB Elevation, Procedural Success, and Mortalityefinition of unsuccessful procedures and thus inability to
ppropriately adjust outcome data. For example, a recent
eta-analysis of seven studies suggested a significant pro-
ressive dose-response relationship between CK-MB eleva-
igure 3. Kaplan-Meier estimates of survival among all patients with and
ithout periprocedural myocardial infarction by type (A, definitions as in
igure 1) and for those with successful procedures only (B). MI 
yocardial infarction.
Table 3. Cox Proportional Hazards Results for
Variable H
All patients (n  5,850)
Any procedural MI*
Unsuccessful procedure
Age (per yr)
Diabetes
Prior MI
Multivessel disease
Successful patients (n  5,735)
Any procedural MI*
Age (per yr)
Diabetes
Prior MI
Multivessel disease
Data presented with any myocardial infarction (MI) versus n
“MI type” as a dummy variable was significant.ions and subsequent mortality (10). Unfortunately, three of
he studies used for this analysis did not adjust for procedure
uccess and two others excluded only patients who died or
equired emergency bypass surgery. Moreover, one of these
tudies included patients with abrupt closure or large spon-
aneous preprocedure MI among the cardiac deaths at one
ear, accounting for 4 of 13 deaths (11). In another
ase-control study, 17% of periprocedural MI patients had
nal Thrombolysis In Myocardial Infarction coronary flow
rade 3 (5). It is unlikely that the prognostic value of
eriprocedural MI in such patients with unsuccessful pro-
edures can be extended to patients who have an isolated
K-MB elevation after an otherwise successful interven-
ion.
The current study highlights the interaction of procedure
uccess with the relationship of periprocedural MI and
ortality during the first year. Similar to a recent report by
tone et al. (3), the effect on unadjusted early mortality in
ur study was significant only after large MI. The difference
n our study is the adjustment for unsuccessful procedures
nd the demonstration that these large MIs are almost
lways associated with clearly recognizable angiographic
omplications or early clinical events rather than otherwise
uccessful procedures (7).
I after successful PCI and mortality association. The
.4% risk attributable to MI after successful procedures was
ot statistically significant in our study, but this does not
xclude a potential clinical difference. It is also possible that
ore effect would be seen beyond one year, as noted in other
tudies (4). This has focused attention on periprocedural
K-MB elevation as a marker for other causes of mortality,
ith diffuse atherosclerosis the leading contender for such
n explanation (12). Failed microvascular perfusion, which
as been shown to have an imperfect correlation with
K-MB elevation and a significant association with early
nd late clinical outcomes, may provide another (13). Our
tudy suggests that in the first year these contributions are
mall relative to those resulting from more easily identified
nsuccessful procedures.
-Year Mortality
Ratio 95% Confidence Interval
3 0.85–2.07
3 2.87–11.04
6 1.04–1.08
0 1.32–3.03
3 1.23–2.74
7 1.18–2.66
5 0.70–1.30
6 1.04–1.08
7 1.34–3.22
6 1.21–2.84
1 1.11–2.62
forced into the model. *Neither “any MI” versus “no MI” orOne
azard
1.3
5.6
1.0
2.0
1.8
1.7
0.9
1.0
2.0
1.8
1.7
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CK-MB Elevation, Procedural Success, and Mortality September 15, 2004:1210–4linical implications. It is intuitive that no MI should be
onsidered inconsequential, and available options to avoid
ll procedural MIs should be exercised. Our study directs
ttention to the special importance of these events in the
etting of recognizable angiographic and early clinical com-
lications. Given that these complications cannot always be
redicted, therapies shown to reduce periprocedural MI and
ngiographic complications, such as glycoprotein IIb/IIIa
nhibitors, should perhaps be considered routinely (14–16).
Finally, what should we tell patients who sustain CK-MB
levation despite these efforts and otherwise have a success-
ul procedure? Our results show that these patients are not
t significantly higher risk of death in the next year and
dditional monitoring or specific pharmacologic manage-
ent is probably not indicated. Their mortality risk is
etermined more by other factors, such as previous sponta-
eous MI, baseline left ventricular dysfunction, presence of
iabetes, and multivessel disease, and therapy should be
irected at secondary prevention of recurrent events.
tudy limitations. Although provocative, our study has
everal limitations. It represents a pooled analysis of multi-
le PCI trials involving coronary stenting of lower risk
atients; the results thus may not be generalizable to other
opulations with higher baseline risk. The studies pooled
or this analysis were conducted before widespread use of
lycoprotein IIb/IIIa inhibitors, so the effect of these agents
n outcomes cannot be evaluated. Clinical follow-up was
imited to the first year after the procedure. Longer
ollow-up may show a more significant association of
eriprocedural MI and mortality regardless of procedure
uccess, but it would still be uncertain whether the effect of
eriprocedural MI is causal or confounded by other clinical
actors.
eprint requests and correspondence: Dr. Donald E. Cutlip,
nterventional Cardiology Section, Beth Israel Deaconess Medical
enter, One Deaconess Road, Baker 4, Boston, Massachusetts
2215. E-mail: dcutlip@bidmc.harvard.edu.
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